Navigation Links
Sun Pharmaceutical Extends Tender Offer for Taro
Date:3/20/2009

MUMBAI, India, March 20 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced its subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), has extended the Expiration Date of the Tender Offer for the purchase of all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro). The Offer will now expire at 5:00 p.m., New York City time, on Friday, April 3, 2009, unless further extended or earlier terminated. The Tender Offer was extended to comply with a continuing order issued by the Supreme Court of Israel temporarily prohibiting the closing of the Offer until the Supreme Court issues a decision on the appeal of the litigation commenced against Alkaloida and its affiliates by Taro and certain of its directors regarding the applicability of the special tender offer rules under the Israeli Companies Law to the Offer. The Tel-Aviv District Court had previously ruled in favor of Sun that a special tender offer was not required.

The mediation process between the parties to the litigation and the Levitt and Moros families, entered into at the recommendation of the Supreme Court, is ongoing. If the temporary order remains in effect on April 3, 2009, Sun expects to extend the Offer while the temporary order remains outstanding.

The Offer was commenced on June 30, 2008 in order to comply with the terms of the Option Agreement between Alkaloida and the controlling shareholders of Taro. Alkaloida exercised its options to acquire shares of Taro from the controlling shareholders on June 25, 2008. The Option Agreement required Alkaloida, promptly after exercising the options, to commence a tender offer at USD 7.75 per Ordinary Share of Taro held by other shareholders. The Offer had previously been scheduled to expire at 5:00 p.m., New York City time, on Friday, March 20, 2009. As of 5:00 p.m., New York City time, on March
'/>"/>

SOURCE Sun Pharmaceutical Industries, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Come see, swim in, and soak ... that competitive edge and to continue to be the most decorated ... Tubs will be on display at The Toledo Hot Tub, Swim ... Rec Center. , Tim Baele, Regional Sales Manager for Master Spas, ... the best place to see hundreds of great products and build ...
(Date:7/24/2014)... Hayes, Inc. ( http://www.hayesinc.com ), a leader ... evidence, is pleased to announce that Dee Donatelli, Senior ... at the AHRMM14 Conference in Orlando, FL, ... value analysis who also serves as the current President ... will facilitate and participate in two preconference sessions on ...
(Date:7/24/2014)... 24, 2014 Angeldress.co.uk, a renowned wedding ... worldwide ladies to obtain their dream garments at affordable ... best special occasion outfits for clients from all over ... the latest designs and the information on how to ... , Recently, the company has unveiled its new collection ...
(Date:7/24/2014)... 2014 In response to a ... patients may benefit from parathyroidectomy, Dr. Babak Larian ... Beverly Hills today commented on hyperparathyroidism, a commonly ... misdiagnosed because its symptoms are vague and similar ... who have been diagnosed with fibromyalgia may actually ...
(Date:7/24/2014)... Osteoporosis is one of the most devious diseases ... as recent research goes, there are now many factors ... than post-menopause and lack of calcium intake. Older people now ... some point in their lives. , However, that does not ... Alsop was a former sufferer who had managed to rebuild ...
Breaking Medicine News(10 mins):Health News:See the New Michael Phelps Swim Spas and Hot Tubs at The Toledo Hot Tub, Swim Spa, Pool & Patio Show at the Lucas County Rec Center this Weekend 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 3Health News:Angeldress.co.uk, A Renowned Wedding Dress Manufacturer And Retailer, Vows To Offer The Best Bridesmaid Dresses For Ladies 2Health News:Is Hyperparathyroidism Misdiagnosed as Fibromyalgia? 2Health News:Is Hyperparathyroidism Misdiagnosed as Fibromyalgia? 3Health News:The Truth About Osteoporosis Review | The Ultimate Secret to Treating Osteoporosis in a Natural and Safe Manner – Vinamy.com 2Health News:The Truth About Osteoporosis Review | The Ultimate Secret to Treating Osteoporosis in a Natural and Safe Manner – Vinamy.com 3
... breakthrough that may aid treatment of learning impairments, strokes, ... that brain nerve stimulation accelerates learning in laboratory tests. ... the April 14 issue of Neuron , involves ... complete. Researchers monitoring brain activity in rats found that ...
... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) ... supplements, such as multivitamins and calcium, and their use jumped ... government report. Between 1994 and 2006, the proportion of ... percent of adults to 53 percent, according to the U.S. ...
... Russians were faced with more than the demise of a ... country saw a 40 percent surge in deaths between 1990 ... much was clear. And for years, many economists and political ... driving those men to drink. They reasoned that privatization left ...
... , To ensure normal fetal development and prevent disease, it is ... time intervals. Researchers in Professor Kristian Helin,s group at BRIC, University ... activity of our genes. The results are just published in the ... ,The complete human genetic code was mapped in 2000. However, it ...
... optimistic; down the opposite. Right is honest and trustworthy. ... tell us. "We use mental metaphors to structure our ... of those metaphors is space." But we ... Rather, "people associate goodness with the side they can ...
... April 13 (HealthDay News) -- Bouts of near-intolerable itching are a ... a broken bone, but you need to be careful how you ... stick anything into your cast to scratch an itch. Never. I ... and chopsticks to forks and brushes," Dr. Paul Prinz, an orthopedic ...
Cached Medicine News:Health News:Making temporary changes to brain could speed up learning, study reports 2Health News:Making temporary changes to brain could speed up learning, study reports 3Health News:Use of Dietary Supplements Keeps Climbing: CDC 2Health News:Use of Dietary Supplements Keeps Climbing: CDC 3Health News:Stanford research casts sober light on Russia's mortality crisis 2Health News:Stanford research casts sober light on Russia's mortality crisis 3Health News:The TET1 enzyme steers us through fetal development and fights cancer 2Health News:Are your values right or left? The answer is more literal than you think 2
(Date:7/24/2014)... DIEGO , July 24, 2014 ... industry leader in bioactive lipid-targeted therapeutics, reported interim ... where ASONEP™ is being investigated as a treatment ... that have failed at least one therapy involving ... no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), ...
(Date:7/24/2014)... , Revenues from continuing operations of ... diluted EPS from continuing operations of $1.08, up 1.9% versus  ... of $0.92, 7% below prior year , Cash from ... , Full year 2014 revenues now expected to be up ... , Full year 2014 adjusted diluted EPS range narrowed to  ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes are against the same ... $701 million.  Sales grew organically by 2%, and changes in ... growth. , By business unit, organic sales growth was ... Commercial. , Reported diluted EPS was $1.11 compared to ... EPS in Q2 2014 was also $1.11 compared to $1.05 ...
Breaking Medicine Technology:Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12
... 1 NeurogesX, Inc. (Nasdaq: NGSX ), a ... management therapies, announced today that Anthony DiTonno, President and ... Fourth Annual JMP Securities Healthcare Focus Conference, to be ... City. , Mr. DiTonno and Stephen Ghiglieri, Chief Financial ...
... Prix Galien USA committee celebrated members of the science ... discovery of drugs and technologies that improve the human ... with the 2009 Prix Galien USA, considered the industry,s ... that could change the course of health care worldwide. ...
Cached Medicine Technology:NeurogesX to Present at JMP Securities Healthcare Focus Conference 2NeurogesX to Present at JMP Securities Healthcare Focus Conference 3Prix Galien USA Honors Innovation in Science and Biotech Industries 2
... GORE SEAMGUARD® Staple Line Reinforcement ... in reducing postoperative pulmonary air leaks ... hospital care. This inert, biocompatible, ePTFE ... non-biological.,It is easy to load and ...
... for the repair of abdominal hernias. It ... two distinct sides. One side of ... of sodium hyaluronate and carboxymethylcellulose (similar to ... side is bioresorbable, providing a temporary physical ...
... Company, we recognize that there are circumstances ... in-growth between the prosthesis and the repair ... all the products in Bards complete line ... proven, versatile repair.,The Reconix Patch is Bards ...
... PLUS Biomaterial is the first hernia ... controlling potential operative contamination of the ... two antimicrobial preservative agents, silver carbonate ... inhibit bacterial colonization on the patch ...
Medicine Products: